Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$800000.0.

  • Myriad Genetics' Change in Account Payables rose 7777.78% to -$800000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 180000.0%. This contributed to the annual value of $4.7 million for FY2024, which is 22702.7% up from last year.
  • Latest data reveals that Myriad Genetics reported Change in Account Payables of -$800000.0 as of Q3 2025, which was up 7777.78% from $3.6 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Change in Account Payables high stood at $14.0 million for Q4 2021, and its period low was -$12.9 million during Q3 2021.
  • In the last 5 years, Myriad Genetics' Change in Account Payables had a median value of -$250000.0 in 2021 and averaged $527777.8.
  • Per our database at Business Quant, Myriad Genetics' Change in Account Payables skyrocketed by 126666.67% in 2021 and then tumbled by 116666.67% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Change in Account Payables stood at $14.0 million in 2021, then plummeted by 117.14% to -$2.4 million in 2022, then tumbled by 145.83% to -$5.9 million in 2023, then skyrocketed by 81.36% to -$1.1 million in 2024, then grew by 27.27% to -$800000.0 in 2025.
  • Its Change in Account Payables was -$800000.0 in Q3 2025, compared to $3.6 million in Q2 2025 and -$1.1 million in Q4 2024.